First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapy vs combination chemotherapy

Table 5 Adverse events of each regimen according to elderly and very elderly

Adverse events	Gemcitabine mono, n = 45		GA & FOLFIRINOX, n = 59		P value
	Elderly, n = 25	Very elderly, n = 20	Elderly, n = 49	Very elderly, n = 10	Elderly	Very elderly
Admission	13 (28.9)		21 (35.6)		0.475
	6 (24.0)	7 (35.0)	18 (36.7)	3 (30.0)	0.275	0.793
Thromboembolism	4 (8.9)		9 (15.3)		0.336
	2 (8.0)	2 (10.0)	7 (14.3)	2 (20.0)	0.441	0.465
Neuropathy (Grade 1,2/3,4)	0 (0.0)		28 (47.5)		0.000*
	(0/0)		(13/15)
	0 (0.0)	0 (0.0)	23 (46.9)	5 (50.0)	0.000*	0.001a
	(0/0)	(0/0)	(9/14)	(4/1)
Neutropenia (Grade 1,2/3,4)	18 (40.0)		47 (79.7)		0.000*
	(9/9)		(16/31)
	9 (36.0)	9 (45.0)	38 (77.6)	9 (90.0)	0.000*	0.038a
	(4/5)	(5/4)	(11/27)	(5/4)
Thrombocytopenia (Grade 1,2/3,4)	24 (53.3)		23 (39.0)		0.312
	(14/10)		(11/12)
	12 (48.0) (8/4)	12 (60.0) (6/6)	19 (38.8) (9/10)	4 (40.0) (2/2)	0.806	0.370
Nausea (Grade 1,2/3,4)	12 (26.6)		16 (27.1)		0.655
	(11/1)		(12/4)
	5 (20.0)	7 (35.0)	14 (28.6)	2 (20.0)	0.236	0.354
	(5/0)	(6/1)	(10/4)	(2/0)
Fatigue (Grade 1,2/3,4)	22 (48.9)		38 (64.4)		0.171
	(12/10)		(21/17)
	11 (44.0)	11 (55.0)	32 (65.3)	6 (60.0)	0.101	0.669
	(7/4)	(5/6)	(19/13)	(2/4)
Diarrhea (Grade 1,2/3,4)	8 (17.8)		15 (25.4)		0.180
	(7/1)		(9/6)
	5 (20.0)	3 (15.0)	12 (24.5)	3 (30.0)	0.635	0.074
	(4/1)	(3/0)	(9/3)	(0/3)
Colitis/pneumonia	9 (20.0)		13 (22.0)		0.906
	(2/7)		(4/9)
	3 (12.0)	6 (30.0)	12 (24.5)	1 (10.0)	0.205	0.134
	(1/2)	(1/5)	(3/9)	(1/0)

Data are presented as: n (%).

^aP < 0.05. GA: Gemcitabine plus nab-paclitaxel.